Dr. Barbara Burtness chaired a session at #AACR26 on “Advancing Precision Approaches to Head and Neck Cancers,” and presented data on #HPV-independent #HNSCC. @theaacr.bsky.social @oncoalert.bsky.social
At #AACR26, @sundarraghav.bsky.social, highlighted how peritoneal metastases are polyclonal, with immune-genomic heterogeneity. Precision strategies for peritoneal metastases are urgently needed. @theaacr.bsky.social @oncoalert.bsky.social
Dr. Barbara Burtness shares Phase 2 data combining the IO102-IO103 cancer vaccine w pembrolizumab in resectable head and neck cancer. The approach was well tolerated, with early signals of response. #AACR26 @theaacr.bsky.social @oncoalert.bsky.social
Dr. Patricia LoRusso reports early first-in-human results for ZW191, showing encouraging responses (~52% ORR) and manageable safety in patients whose cancers had already been treated with multiple prior therapies. #AACR26
@theaacr.bsky.social @oncoalert.bsky.social
At #AACR26, Ece Koçak and Dr. Megan King share how PARP inhibitors increase DNA “bridges” in BRCA-deficient cancer cells that can rupture the nucleus, exposing DNA and triggering immune signaling. @mcdb-yale.bsky.social @theaacr.bsky.social @oncoalert.bsky.social
New research presented by Kira Glasmacher and
Jeffrey Townsend maps how #coloncancer develops, showing which mutations happen early vs. later. #AACR26
@theaacr.bsky.social @yalesph.bsky.social @oncoalert.bsky.social
Miguel López de Rodas Gregorio presents a new tool called SCRIBE to improve cancer biomarker discovery by testing how consistent results are across different cut-points.
@theaacr.bsky.social @yalepathology.bsky.social @oncoalert.bsky.social
María Villalba Esparza shows that low oxygen #hypoxia in tumors affects T cells differently over time. #AACR26 @yalepathology.bsky.social @theaacr.bsky.social @oncoalert.bsky.social
New research presented by Daulet Aiyymnayev @yalepathology.bsky.social at #AACR26 shows that loss of BAP1 in uveal #melanoma reshapes gene regulation and cell identity. It switches tumor cells away from a normal state toward a more invasive state. @theaacr.bsky.social @oncoalert.bsky.social
Suchitra Krishnan-Sarin joined leaders at #AACR26 to share ways to reduce modifiable risk factors, address barriers & implement policy to reduce the impact of #tobacco use. @theaacr.bsky.social @oncoalert.bsky.social
Rong Fan @yalembb.bsky.social opens #AACR26 symposium on “Cutting-Edge Advances in Hematology,” with key advances shaping #hematology. @yalepathology.bsky.social @yale-hematology.bsky.social @theaacr.bsky.social @oncoalert.bsky.social
Research from @yalepathology.bsky.social at #AACR26 shows that where immune cells sit in #NSCLC tumors matters. Clustering of CD8+ and CD20+ T cells inside tumors is linked to better survival, and patterns in surrounding tissue may signal worse outcomes. @theaacr.bsky.social @oncoalert.bsky.social
Longgang Zhao, PhD, at #AACR26 highlights metabolic patterns linked to #livercancer risk. Higher levels of certain acids were associated with increased risk, while others showed protective links. @theaacr.bsky.social @oncoalert.bsky.social
New preclinical work presented by Ranjini Sundaram in glioblastoma #GBM models explores overcoming resistance to treatment. #AACR26 @theaacr.bsky.social @oncoalert.bsky.social #AACR26
Based on a challenge in biomarker discovery, Dr. Kim Blenman
presents a call to re-evaluate and improve differential expression #AI tools to ensure more robust, reproducible findings in cancer research. @AACR #AACR26.
Stop by this morning's #AACR26 poster session starting at 9am PST to learn about the research from our presenters: Dr. Lajos Pusztai; Ranjini Sundaram; @ZhaoLonggang; @Elham_Samami; Dr. Pat LoRusso; and Gabriela Esnaola @ishizukalab! @SmilowCancer @AACR
At #AACR26, Mengni He @yalepathology.bsky.social
shares how spatial transcriptomics explains response vs resistance to sacituzumab govitecan for metastatic #breastcancer #MBC.
@theaacr.bsky.social @oncoalert.bsky.social
Newly presented #AACR26 miPEP133 emerges as a potential tumor suppressor in #ovariancancer. Restoring its expression slowed tumor cell growth and increased sensitivity to chemotherapy and MEK inhibitors.
@theaacr.bsky.social @oncoalert.bsky.social
At #AACR26, new findings shared by Yan Gu show clonal diversity isn’t just noise, it fuels growth in #lungcancer. Mixed tumor cell populations grew faster than single clones, with integrin-mediated signaling playing a key role.
@theaacr.bsky.social @oncoalert.bsky.social
At @theaacr.bsky.social's James S. Ewing–Thelma B. Dunn Lecture in Pathology #AACR26, Dr. David Rimm @yalepathology.bsky.social highlighted a shift in #pathology from subjective “reading” to precise measurement.
@oncoalert.bsky.social
Earlier at #AACR26, Dr. Roy Herbst led a town hall on policy issues shaping #cancer research: funding, global collaboration + workforce challenges, with Jon Retzlaff @theaacr.bsky.social, Dr. Patty Spears #UNCLineberger, Dr. Cornelia Ulrich @huntsmancancer.bsky.social, and @ejohnwherry.bsky.social.
Jack Robbins shares how the use of spatial transcriptomics reveals response vs resistance to T-DXd in metastatic #breastcancer #MBC. #AACR26
@yalepathology.bsky.social @theaacr.bsky.social @oncoalert.bsky.social
New research shared by Dan McQuaid
@muzumdarlab.bsky.social links #obesity-driven #pancreaticcancer to dysregulation of the hormone cholecystokinin (CCK). #AACR26
@theaacr.bsky.social @oncoalert.bsky.social
@yalepathology.bsky.social presents AI-driven analysis of TILs in #NSCLC, showing promise as a biomarker for immunotherapy response. Quantitative TIL scoring linked to ⬆️ survival, showing potential of quantitative clinical readings in #pathology. #AACR26 @theaacr.bsky.social @oncoalert.bsky.social
An analysis of #melanomas by the Dr. Jeff Townsend
lab shows aging shapes tumor evolution less by mutation rate and more by changes in selection. Yihan Liu shares how driver mutations shift with age + how tumor biology, treatment strategies evolve. #AACR26
@theaacr.bsky.social @oncoalert.bsky.social
At #AACR26, new research from the lab of Dr. Jeff Townsend
presented by Meng Liu, shows how measuring the selective advantage of copy number amplifications can better pinpoint drivers in #ovariancancer.
@theaacr.bsky.social @oncoalert.bsky.social
New research on #HIV + #cancer presented by
Katherine Ma at #AACR26 links HIV-associated clonal hematopoiesis to abnormal T cell growth. DNMT3A mutations may drive expansion of CD4+ T cells + could ⬆️ cancer risk despite suppressive antiretroviral therapy.
@theaacr.bsky.social @oncoalert.bsky.social
Daniel A. Colón Ríos presents research at #AACR26 showing how IDH1-mutant cancers develop resistance to #PARP inhibitors. Work from the #GlazerLab identified key pathways behind PARPi resistance any d points to potential strategies to overcome it.
@theaacr.bsky.social @oncoalert.bsky.social
Dr. Roy Herbst moderates a major symposium this afternoon at 3pm PST #AACR26: Researcher Town Hall: Navigating Policy Challenges and Securing Funding.
abstractsonline.com/pp8/#!/21436...
@theaacr.bsky.social
Congratulations Dr. Samir Zaidi, recipient of an @theaacr.bsky.social Trailblazer Cancer Research Grant for Early-Stage Investigators to support his project, "Mechanisms of cellular plasticity in neuroendocrine prostate cancer initiation." #AACR26
aacr.org/about-the-aa...